USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $-0.40 | $-0.35 | $-0.23 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $22.97M | $22.76M | $15.22M |
Castle Biosciences, Inc's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $-0.39 | $-0.48 | $-0.19 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $-1.35 | $-1.49 | $-1.22 |
| Dec 2022 | 6 | $-1.11 | $-2.14 | $-0.36 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-0.39 | $-0.30 | $-0.30 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-1.35 | $-1.22 | $-1.22 |
| Dec 2022 | 0 / 0 | $-1.11 | $-0.76 | $-0.76 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $24.08M | $23.30M | $27.40M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 5 | $91.86M | $91.00M | $92.98M |
| Dec 2022 | 6 | $112.45M | $104.50M | $121.10M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $-0.40 | - | - |
| Aug 9, 2021 | Jun 2021 | $-0.37 | $-0.35 | 4.37% |
| May 10, 2021 | Mar 2021 | $-0.24 | $-0.17 | 27.66% |
| Mar 8, 2021 | Dec 2020 | $-0.12 | $-0.23 | -88.52% |
| Nov 9, 2020 | Sep 2020 | $-0.12 | $-0.23 | -100.00% |
| Aug 10, 2020 | Jun 2020 | $-0.40 | $-0.08 | 79.87% |
| May 11, 2020 | Mar 2020 | $-0.15 | $0.03 | 120.34% |
| Mar 10, 2020 | Dec 2019 | $-0.20 | $0.11 | 154.11% |
| Nov 11, 2019 | Sep 2019 | $-0.31 | $0.05 | 116.39% |
| Sep 3, 2019 | Jun 2019 | $-0.79 | $-0.13 | 83.13% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 8, 2021 | Dec 2020 | $-0.41 | $-0.51 | - |
| Mar 10, 2020 | Dec 2019 | $-1.37 | $0.03 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $22.97M | - | - |
| Aug 9, 2021 | Jun 2021 | $18.92M | $22.76M | 1.20% |
| May 10, 2021 | Mar 2021 | $22.81M | $22.81M | 1.00% |
| Mar 8, 2021 | Dec 2020 | $15.74M | $17.30M | 1.10% |
| Nov 9, 2020 | Sep 2020 | $14.99M | $15.22M | 1.02% |
| Aug 10, 2020 | Jun 2020 | $8.80M | $12.71M | 1.44% |
| May 11, 2020 | Mar 2020 | $13.79M | $17.42M | 1.26% |
| Mar 10, 2020 | Dec 2019 | $0.00 | $17.63M | - |
| Nov 11, 2019 | Sep 2019 | $9.45M | $14.77M | 1.56% |
| Sep 3, 2019 | Jun 2019 | $10.74M | $10.74M | 1.00% |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 8, 2021 | Dec 2020 | $61.12M | $62.65M | 2.50% |
| Mar 10, 2020 | Dec 2019 | $0.00 | $51.87M | - |
CSTL's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 6 analysts, the average EPS estimation for Castle Biosciences, Inc's next quarterly earnings is $-0.40, with a low EPS estimation of $-0.49, and a high estimation of $-0.32.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.40, the last 2 month trend is $-0.34, and the 3 month trend is $-0.34.
Based on 6 analysts, the average revenue estimation is $22.97M, with a low revenue estimation of $22.10M, and a high estimation of $23.82M.
Castle Biosciences, Inc's previous earnings date was Aug 9, 2021 for its fiscal quarter ended Jun 30, 2021.
CSTL's earnings per share (EPS) was $-0.35, beating the consensus analysts forecast of $-0.37 by 4.37%.
The EPS was lower than the previous fiscal quarter (Mar 2021) by 105.88%, and lower than the same period a year before (Jun 2020) by 337.50%.
Revenues were $22.76M, better than the forecast of $18.92M by 20.29%, down by -0.24% from the previous quarter , and up by 78.99% from the same period last year.
The company reported a net income of $-8.79M.Free cash flow for the quarter was $-11.73M , compared to $-4.38M last quarter and $11.74M a year before.
Castle Biosciences, Inc's previous annual earnings date was Mar 8, 2021 for its fiscal year ended Dec 31, 2020.
CSTL's earnings per share (EPS) was $-0.51, missing the consensus analysts forecast of $-0.41 by 24.39% , and lower than the previous year's EPS (Dec 2019) by -1968.13%.
Revenues were $62.65M, better than the forecast of $61.12M by 2.50%, and up by 20.79% from previous year's revenue.
The company reported a net income of $-10.28M.
Castle Biosciences, Inc reported a free cash flow of $5.11M for its fiscal year, compared to $6.08M a year ago.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
